- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01122771
Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh
A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
Study Overview
Status
Conditions
Detailed Description
Visceral leishmaniasis (VL) is the most severe form of leishmaniasis. The causative parasite in Bangladesh is almost exclusively L. donovani.
• The current treatment options in Bangladesh are not satisfactory as they are either toxic and long, or are of limited use in women of childbearing age due to possible teratogenicity, long treatment duration which leads to non-compliance and possible emergence of resistance or expensive.
In collaboration with Indian Medical Research Council and investigators in India, DNDi initiated a combination trial for treatment of VL in Bihar, India in 2008 including 624 patients from age 5 - 60. The same combinations will be used in the present study. An interim safety review was conducted on the first 120 patients included in the Indian VL Combination study and revealed no safety issues with combination treatment. The enrolment is complete and the final results for 624 patients are expected in Q1 2010.
This is a randomized, controlled, open-label, parallel group study to compare the safety and efficacy of different combination regimens with AmBisome for the treatment of VL in Bangladesh.
This trial is designed in two steps:
Step 1: First 120 patients will be recruited in a hospital setting in a study including parasitology and laboratory assessments at Community Based Medical College, Bangladesh (CBMC,B), primarily for the purpose of reconfirming the safety of combination treatments in Bangladesh. Pending the review and approval of an independent DSMB of the Day 45 data, step 2 will commence.
Step 2: Approximately 554 Patients will then be recruited and treated in Upazilla Health Centre's (UZHC), situated in endemic regions of Bangladesh. We will use rapid diagnostic test (RDT) and the limited laboratory assessments that are available in the centres.
Female patients will be stratified according to marital status, such that unmarried women of child-bearing age will be stratified to receive treatments that do not contain Miltefosine, and married women will be stratified to receive one of the four treatment regimens and must consent to use an approved method of contraception and undergo pregnancy test at the start of the study. Child-bearing age is defined as achieving menarche.
There will be one planned safety review assessing safety and initial cure at Day 45 following completion of Step 1.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Mymensingh
-
Bhaluka, Mymensingh, Bangladesh
- Bhaluka UZHC
-
Gaffargaon, Mymensingh, Bangladesh
- Gaffargaon
-
Trishal, Mymensingh, Bangladesh
- Community Based Medical College
-
Trishal, Mymensingh, Bangladesh
- Trishal UZHC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- VL proven by parasitological examination of splenic or bone marrow aspirate. Parasite burden to be graded according to Chulay and Bryceson 1983 and subsequently adopted by WHO. (Step 1 only)
- History of fever, for at least 2 weeks with one or more of the followings criteria: Anaemia (5<Hb<10g/dl), Loss of weight, Splenomegaly
- rk39 positive at baseline assessments
- willing and able to attend follow-up visits
- Male or Female age: 5-60 yrs
- Written informed consent from the patient or from patient's parent or guardian if the patient is under 18 yrs, in addition written assent from patients of 11 - 17 yrs of age. If the patient or parent/guardian are illiterate an impartial witness should be present during the consenting procedure and should also sign.
Exclusion Criteria:
- Married women of child-bearing potential (defined as women who have achieved menarche) who are not using an assured method of contraception or are unwilling to use an assured method of contraception for the duration of treatment and three months after. Assured methods of contraception include i.e. IUCD or depot hormone injection of medroxyprogesterone acetate MPA (DepoProvera®)
- Platelet count less than 40,000/mm3 (Step 1 only)
- Prothrombin time 5 seconds or greater than normal range (Step 1 only)
- Known hepatitis B, C or known HIV positive
- Patients who present with Para Kala-azar Dermal Leishmaniasis
- Signs/symptoms indicative of severe VL (Hb < 5gm/dl, etc)
- Patients with a previous history of VL
- Patients who have received any investigational (unlicensed) drugs within the last 3 months
- Severe malnutrition BMI<15 in adults, weight for height less than 60% in children
- Clinical symptoms of chronic underlying disease such as severe cardiac, renal or hepatic impairment
- Positive HRP2/pLDH Combo test for malaria
- Pregnant woman or breast-feeding mother
- Known alcohol or other drug abuse
- Concomitant chronic drug treatment eg. TB, HIV etc.
- Known hypersensitivity to AmBisome, Paromomycin and other aminoglycosides and/or Miltefosine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ambisome
15mg Ambisome on days 1,3 and 5
|
Ambisome i.v.
5mg on days 1, 3 and 5
Other Names:
|
Experimental: Ambisome + Miltefosine
Ambisome 5mg + miltefosine 10 days
|
Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)
Other Names:
|
Experimental: Ambisome +paromomycin
AmBisome IV infusion (single dose, day 1) + Paromomycin base 11mg/kg/day IM (Gland Pharma, India) for 10 days (days 2-11)
|
Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
Other Names:
|
Experimental: Miltefosine + paromomycin
Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
|
Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Definitive cure
Time Frame: 6 month post treatment
|
The primary endpoint variable is definitive cure at month 6, and is defined as no significant clinical signs or symptoms of VL at Day 45 including lack of fever [axiliary temperature < 99.5°F] and at least one of the following:
|
6 month post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Initial Cure
Time Frame: Day 45
|
Initial Cure is defined as no significant clinical signs or symptoms of VL at Day 45 ie lack of fever [axiliary temp < 99.5°F and at least one of the following:
|
Day 45
|
Adverse events
Time Frame: Treatment
|
Assess safety during treatment and follow-up in different healthcare settings
|
Treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ridwanur Rahman, MD, Shaheed Surawardy Medical College
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Skin Diseases, Parasitic
- Skin Diseases, Infectious
- Euglenozoa Infections
- Leishmaniasis
- Leishmaniasis, Visceral
- Anti-Infective Agents
- Antineoplastic Agents
- Anti-Bacterial Agents
- Antifungal Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Amebicides
- Miltefosine
- Paromomycin
- Amphotericin B
- Liposomal amphotericin B
Other Study ID Numbers
- VLCombo-BD-09
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Visceral Leishmaniasis
-
Drugs for Neglected DiseasesNovartis PharmaceuticalsRecruitingPrimary Visceral LeishmaniasisEthiopia
-
Drugs for Neglected DiseasesNovartis PharmaceuticalsRecruiting
-
Drugs for Neglected DiseasesGilead Sciences; Paladin Labs Inc.Completed
-
Drugs for Neglected DiseasesWellcome Trust grant 212346/Z/18/Z - 21st Century Treatments for Sustainable...CompletedVisceral Leishmaniasis | Cutaneous LeishmaniasesUnited Kingdom
-
Centre Hospitalier Universitaire de NiceCompleted
-
IDRIBill and Melinda Gates FoundationCompletedVisceral Leishmaniasis | Post-kala-azar Dermal LeishmaniasisIndia
-
Foundation for Innovative New Diagnostics, SwitzerlandLondon School of Hygiene and Tropical Medicine; Leishmaniasis Research and... and other collaboratorsRecruitingVisceral LeishmaniasisEthiopia
-
Foundation for Innovative New Diagnostics, SwitzerlandKenya Medical Research InstituteRecruitingVisceral LeishmaniasisKenya
-
University of YorkUniversity of Khartoum; Makerere University; European and Developing Countries... and other collaboratorsRecruitingVisceral LeishmaniasisKenya
-
Drugs for Neglected DiseasesMakerere University; The Netherlands Cancer Institute; Kenya Medical Research... and other collaboratorsCompletedVisceral LeishmaniasisEthiopia, Kenya, Sudan, Uganda
Clinical Trials on Liposomal amphotericin B
-
Bharat Serums and Vaccines LimitedMinistry of Science and TechnologyCompletedLeishmaniasis, VisceralIndia
-
Taiwan Liposome CompanyCompleted
-
European Organisation for Research and Treatment...CompletedCancerBelgium, Netherlands, Italy, Hungary, France, Spain, Germany, Israel, Czech Republic, United Arab Emirates, Sweden, Greece, Turkey, Portugal, Slovakia
-
Hospital Universitário Professor Edgard SantosCompleted
-
Drugs for Neglected DiseasesAddis Ababa UniversityTerminatedVisceral LeishmaniasisEthiopia, Sudan
-
Soroka University Medical CenterCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Erasmus Medical CenterGilead Sciences; Nexstar PharmaceuticalsCompleted
-
Gilead SciencesTerminatedFebrile NeutropeniaGreece
-
Banaras Hindu UniversityCompletedVisceral LeishmaniasisIndia